Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.74 Million GBP | 619.46% |
| 2022 | -740 Thousand GBP | -197.19% |
| 2021 | -249 Thousand GBP | -479.07% |
| 2020 | -43 Thousand GBP | -104.18% |
| 2019 | -21.06 Thousand GBP | 23.73% |
| 2018 | -27.61 Thousand GBP | 15.25% |
| 2017 | -32.58 Thousand GBP | -48.82% |
| 2016 | -21.89 Thousand GBP | 0.0% |
| 2015 | - GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| 2013 | - GBP | 0.0% |
| 2012 | - GBP | 100.0% |
| 2011 | -849 Thousand GBP | 22.18% |
| 2010 | -1.09 Million GBP | -61.39% |
| 2009 | -676 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - GBP | -100.0% |
| 2024 Q2 | -434 Thousand GBP | 0.0% |
| 2023 Q3 | -262.5 Thousand GBP | -112.06% |
| 2023 FY | 3.84 Million GBP | 619.46% |
| 2023 Q1 | 2.37 Million GBP | 627.33% |
| 2023 Q2 | 2.17 Million GBP | -8.24% |
| 2023 Q4 | 4.3 Million GBP | 1738.86% |
| 2022 Q2 | -290 Thousand GBP | 0.0% |
| 2022 FY | -740 Thousand GBP | -197.19% |
| 2022 Q4 | -450 Thousand GBP | 0.0% |
| 2022 Q3 | - GBP | 100.0% |
| 2022 Q1 | - GBP | 100.0% |
| 2021 Q2 | -34 Thousand GBP | 0.0% |
| 2021 Q4 | -215 Thousand GBP | 0.0% |
| 2021 Q3 | - GBP | 100.0% |
| 2021 Q1 | - GBP | 100.0% |
| 2021 FY | -249 Thousand GBP | -479.07% |
| 2020 FY | -43 Thousand GBP | -104.18% |
| 2020 Q3 | - GBP | 100.0% |
| 2020 Q4 | -35.68 Thousand GBP | 0.0% |
| 2020 Q2 | -7314.00 GBP | 0.0% |
| 2020 Q1 | - GBP | 0.0% |
| 2019 Q1 | - GBP | 0.0% |
| 2019 FY | -21.06 Thousand GBP | 23.73% |
| 2019 Q2 | - GBP | 0.0% |
| 2019 Q3 | - GBP | 0.0% |
| 2019 Q4 | - GBP | 0.0% |
| 2018 Q2 | - GBP | 0.0% |
| 2018 Q4 | - GBP | 0.0% |
| 2018 Q1 | - GBP | 0.0% |
| 2018 FY | -27.61 Thousand GBP | 15.25% |
| 2018 Q3 | - GBP | 0.0% |
| 2017 Q4 | - GBP | 0.0% |
| 2017 Q1 | - GBP | 0.0% |
| 2017 Q2 | - GBP | 0.0% |
| 2017 Q3 | - GBP | 0.0% |
| 2017 FY | -32.58 Thousand GBP | -48.82% |
| 2016 FY | -21.89 Thousand GBP | 0.0% |
| 2016 Q2 | - GBP | 0.0% |
| 2016 Q3 | - GBP | 0.0% |
| 2016 Q4 | - GBP | 0.0% |
| 2016 Q1 | - GBP | 0.0% |
| 2015 Q2 | - GBP | 0.0% |
| 2015 Q3 | - GBP | 0.0% |
| 2015 FY | - GBP | 0.0% |
| 2015 Q1 | - GBP | 0.0% |
| 2015 Q4 | - GBP | 0.0% |
| 2014 Q3 | - GBP | 0.0% |
| 2014 Q1 | - GBP | 0.0% |
| 2014 Q4 | - GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| 2014 Q2 | - GBP | 0.0% |
| 2013 Q4 | - GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| 2013 Q3 | - GBP | 0.0% |
| 2012 FY | - GBP | 100.0% |
| 2011 FY | -849 Thousand GBP | 22.18% |
| 2010 FY | -1.09 Million GBP | -61.39% |
| 2009 FY | -676 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 68.358% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -152898.066% |
| SQZ Biotechnologies Company | 9.79 Million USD | 51.542% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 59.457% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.015% |
| Mesoblast Limited | -35.16 Million USD | 113.495% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 13997.511% |
| Genus plc | 178.7 Million USD | 97.344% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1057.095% |
| Marizyme, Inc. | 457.7 Thousand USD | -936.919% |
| ContraFect Corporation | -154 Thousand USD | 3181.818% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 43245.455% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 9592.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -6082.827% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -7120.667% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1324.771% |
| MultiCell Technologies, Inc. | 49.32 USD | -9622771.046% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 88.213% |
| EV Biologics, Inc. | 48.9 Thousand USD | -9605.521% |
| Q BioMed Inc. | -8988.00 USD | 52903.738% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 83.203% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 30870.228% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 97.844% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -6680.0% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3919.688% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -7527.037% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 95940.065% |
| Arch Therapeutics, Inc. | -2439.00 USD | 194687.946% |
| IMV Inc. | -962.29 Thousand USD | 593.194% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -3277.936% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4966.944% |
| GB Sciences, Inc. | -624.00 USD | 760676.923% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 5616.808% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.937% |
| Halberd Corporation | -208.00 USD | 2281830.769% |
| Enzolytics Inc. | 30.7 Thousand USD | -15355.256% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -249.705% |
| SYBLEU INC | 11.69 Thousand USD | -40477.975% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -883.764% |
| argenx SE | 1.1 Billion USD | 99.572% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 118.397% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -668.727% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.841% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 53690.786% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 89.301% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 515.743% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -380.374% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 50.619% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 5760.175% |
| BioStem Technologies, Inc. | 15.42 Million USD | 69.231% |
| ONE Bio Corp. | 20.12 Million USD | 76.418% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 40201.394% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 9934.435% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2588.038% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2588.038% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 1022.431% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 853.168% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 16465.517% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -954.566% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1585.413% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -2.995% |
| Bioxytran, Inc. | -8285.00 USD | 57384.249% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1372.386% |
| Neutra Corp. | 14.33 Thousand USD | -33007.778% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 5887.805% |
| PureTech Health plc | -1.6 Million USD | 396.07% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 574.014% |
| IXICO plc | 3.27 Million USD | -45.138% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 783.862% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 364.992% |
| CSL Limited | 7.7 Billion USD | 99.938% |
| Cellectis S.A. | 18 Thousand USD | -26266.667% |